Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Captor Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was zł-2.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł-7.66.
During the past 3 years, the average EBIT per Share Growth Rate was 5.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Captor Therapeutics's EBIT per Share or its related term are showing as below:
WAR:CTX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -350.6 Med: -58.2 Max: 5.1
Current: 5.1
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Captor Therapeutics was 5.10% per year. The lowest was -350.60% per year. And the median was -58.20% per year.
WAR:CTX's 3-Year EBIT Growth Rate is ranked worse than 64.11% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs WAR:CTX: 5.10
Captor Therapeutics (WAR:CTX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Captor Therapeutics EBIT per Share Related Terms
Captor Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Captor Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-7.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Captor Therapeutics (WAR:CTX) has a EBIT per Share of zł-7.66 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Captor Therapeutics and its competitors. According to the industry distribution chart, Captor Therapeutics ranks #752 out of 1173 companies in the Biotechnology industry, placing it in the top 64.1%.
Is Captor Therapeutics' EBIT per Share too high?
Captor Therapeutics' current EBIT per Share is zł-7.66. Based on the distribution chart, Captor Therapeutics ranks #752 out of 1173 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Captor Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Captor Therapeutics ranks #752 out of 1173 companies for EBIT per Share. This places Captor Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Captor Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Captor Therapeutics's current EBIT per Share is zł-7.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.13, compared to a current price of zł73.50 — trading 625.6% above its estimated fair value. The current EBIT per Share is zł-7.66. Captor Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current EBIT per Share is zł-7.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued.
The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13.
GuruFocus considers Captor Therapeutics to be Significantly Overvalued.
Key valuation signals for WAR:CTX:
EBIT per Share: zł-7.66
GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score
Get the complete analysis for WAR:CTX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CTX has been successfully added to your 
